Surf Bio is leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for Diabetes, Oncology, HIV, COVID-19, and other therapeutic areas.
Employees: 1-10
Total raised: $17.6M
Investors 2
| Date | Name | Website |
| 02.11.2022 | Xontogeny | xontogeny.... |
| 24.08.2022 | Breakout V... | breakout.v... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.04.2024 | Grant | $1.6M | - |
| 13.04.2022 | Seed | $16M | - |
Mentions in press and media 3
| Date | Title | Description |
| 30.04.2024 | Surf Bio Receives $1.6M Non-Dilutive Grant From Bill & Melinda Gates Foundation | Surf Bio, a Palo Alto, CA-based biopharmaceutical company commercializing a novel drug stabilization platform, has received a $1.6M grant from the Bill & Melinda Gates Foundation. The company intends to use the amount to evaluate the us... |
| 13.04.2022 | Surf Bio Raises $16M in Seed Financing | Surf Bio, a Palo Alto, CA-based biopharmaceutical company, raised $16M in Seed funding. The round was led by Breakout Ventures and Perceptive Xontogeny Venture Fund. The company intends to use the funds advance its polymer-based drug delive... |
| 12.04.2022 | Surf Bio Lands $16M Seed Financing | PALO ALTO, CA, Surf Bio, a biopharmaceutical company commercializing a novel drug stabilization platform, today announced a $16 million Series Seed round of funding. >> Click here for more funding data on Surf Bio >> To expo... |